• Username (E-mail)
  • Password
Dow 19,827 -0.3%  EStoxx50 3,285 -0.3%  Nikkei 18,814 -1.5%  EUR 1.0708 0.0% 
Nasdaq 5,539 -0.6%  FTSE100 7,220 -1.5%  Yen 112.7080 0.0%  Oil 55.5 -0.4% 
S&P500 2,268 -0.3%  DAX 11,540 -0.1%  GBP 1.2401 0.0%  Gold 1,216 0.0% 

Amgen share [Symbol: AMGN / ISIN: US0311621009]

Realtimequote Amgen Inc. in USD

Exchange Market
154.81
Last
168,504
Volume
Time 03:59 PM
01/17/2017 03:59:58 PM UTC-0500
activate push

Stock Price Amgen Inc. in USD

Activate push
154.80 USD -1.32 USD -0.85 %
Trade Time 5:20 PM Trade Date 1/17/2017
Daily High 156.10 Open 155.14
Daily Low 153.55 Prev. Close 154.80
52-week High 176.85 Volume (Qty.) 1,090,070
52-week Low 133.64 Market Cap (USD) 116.32 B
52-week Perf.
Exchange

Analyst Opinions for Amgen Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
08/26/13
Amgen Independent Research GmbH
04/03/13
Amgen Independent Research GmbH
02/15/13
Amgen Independent Research GmbH
12/17/12
Amgen RBC Capital Markets
12/17/12
Amgen Independent Research GmbH

Moody's Rating for Amgen Inc.

Investment Grade (High Grade)
Investment Grade (Medium Grade)
Speculative Grade
Rating Baa1
Rating Update NEW
Date of Rating 2/23/2016
Rating Office USA

Profile Amgen Inc.

Company Profile
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. Its products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
pagehit

Add or Edit Instrument

Amgen Chart - 1 Year - NAS
  • Intraday
  • 1w
  • 3 Mo.
  • 1y
  • 3y
  • 5y
  • Max
  • Exchange: NAS
  • Chart Options

Estimates for Amgen

2015 2016e 2017e
Dividend 3.16 3.91 4.39
Dividend Yield in % 1.93 2.52 2.83
P/E Ratio 15.80 13.44 12.46
EPS 10.38 11.55 12.46

Amgen Key Figures

Market Cap (USD) 116.32 B
Free Float in % 99.82
Number of Shares (Mio.) 743.92
Cash Flow per Share 11.21
Book Value per Share 37.45
60-Days Volatility 37.94
P/B Ratio 4.38

Base Data Amgen

Symbol AMGN
ISIN US0311621009
Indices NASDAQ 100, S&P 100, BX Swiss - USA, NASDAQ Comp., S&P 500

About the Company Amgen

Country USA

Amgen Historical Prices

01/12/2017
01/12/2017 06:00:00 PM UTC-0500
156.12 1,090,127
01/11/2017
01/11/2017 06:00:00 PM UTC-0500
155.36 1,118,178
01/10/2017
01/10/2017 06:00:00 PM UTC-0500
156.62 1,524,326
01/09/2017
01/09/2017 06:00:00 PM UTC-0500
158.76 1,210,272
01/08/2017
01/08/2017 06:00:00 PM UTC-0500
158.84 1,211,465

Amgen Peer Group

Agennix 0.04
25.8%
Amgen 154.80
-0.8%
BB BIOTECH 54.20
-1.9%
Bayer 100.70
-0.4%
Biogen 283.01
-0.6%
Biotest 17.10
5.2%
EVOTEC 7.63
-1.2%
Gilead Sciences 71.91
-1.6%
MorphoSys 47.90
-0.7%
QIAGEN 26.09
-2.2%
QIAGEN 26.09
-2.2%
Sanofi 76.10
-1.1%

Similar shares with higher 1-year perf.